You are here: Industry Insights > Immuno-Oncology

News List

BI snaps up OSE’s novel checkpoint inhibitor pharmatimes
July 18, 2018
Boehringer Ingelheim and OSE Immunotherapeutics have joined forced to develop OSE-172, a novel checkpoint inhibitor antibody targeting myeloid lineage cells for the treatment of advanced solid tumours.
BMS' Opdivo becomes first immuno-oncology agent available in China pharmafile
June 22, 2018
Bristol-Myers Squibb’s flagship immunotherapy Opdivo (nivolumab) has broken ground to become the first and only PD-1 inhibitor to be made available in China.
How different are I-O stars from Merck, Roche and Bristol-Myers? Depends who you ask fiercepharma
June 07, 2018
It’s no secret that most ASCO watchers decided Merck's data on immuno-oncology star Keytruda would cement its position as king of the all-important lung cancer market.
LUYE pharma Joins US Firm to Develop Immuno-oncology Treatments biospectrumasia
May 30, 2018
The most advanced next generation dual-targeted CAR-T cell therapy drug derived from the Collaboration is in the IND enabling preclinical study stage
3 Hottest Areas of Drug Development to Keep an Eye on in 2018 biospace
December 21, 2017
Arpita Dutt, writing for Zacks, predicts what the three hot areas for approvals are likely to be in 2018.
Opening Ceremony of CStone Pharmaceuticals' Suzhou Translational Medicine Research Center and an ass prnasia
November 03, 2017
CStone Suzhou Translational Medicine Research Center (TMRC) was officially launched in Suzhou Industrial Park on October 28, 2017.
Compugen, Mount Sinai Collaborate on Novel Myeloid Immuno-Oncology Targets americanpharmaceuticacreview
November 03, 2017
Myeloid cells are a critical component of the immunosuppressive tumor microenvironment (TME), preventing T cells from entering the tumor and eliciting an immune response against the tumor.
Bristol-Myers and Halozyme to develop subcutaneous immuno-oncology drugs pharmaceufical-technology
September 18, 2017
The Enhanze technology is based on Halozyme’s patented recombinant human hyaluronidase enzyme (rHuPH20) that removes traditional limitations on the volume of biologics that can be delivered subcutaneously.
Can the culprit for cancer spreading also boost immuno-oncology treatments? fiercebiotech
September 14, 2017
Lymphatic vessels are tiny valved structures that transport and drain fluid from the body—but they are also blamed for carrying cancer cells from the primary tumor to other locations in the body.
Armo taps Celgene, GV for $67M to fuel late-phase I-O R&D fiercebiotech
August 31, 2017
Armo will use the money to run phase 2/3 trials in renal cell and non-small cell lung cancer.

Previous page 1 2 3 4 5 6 7 8 9 10 Next page